Register to gain access to personalised information regarding Brand, the indications your are treating regularly, dosing guidelines and resources such as Major Studies, Patient Information and short videos curated to your special interest.

Prevention of Atherothrombotic Events in Peripheral Artery Disease

Xarelto is indicated for the prevention of atherothrombotic events in adults with symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.1

Protection starts with getting to know your patient

How do you protect your patients like Roberto?

MRA scan image taken with permission and adapted from: Dr. med. Reimund Parsche, Ruppiner Kliniken GmbH and Radiological Practice, Neuruppin, Germany.

What does the future look like for your patients after revascularisation?

Are you aware of the risks your patients face?

Improve the outcomes that matter most for patients like Roberto

What does long-term protection look like to you?

* Primary composite efficacy outcome of ALI, major amputation of vascular aetiology, MI, ischaemic stroke or CV death. † RRR was calculated as 1-HR.

How many could benefit?

See how your patients could benefit from the protection you provide

For 1000 patients with PAD post-revascularisation Xarelto vascular dose 2.5 mg BID plus aspirin 100 mg OD over one year:2

would prevent 36 major adverse vascular events^*
would cause 3 TIMI major bleeding vs aspirin 100mg OD^†

* Primary composite efficacy outcome of ALI, major amputation of vascular aetiology, MI, ischaemic stroke or CV death.

† Primary safety outcome

Protection for your patients continues immediately after revascularisation

Protect your patients against major adverse vascular events

Prescribe immediately after revascularization*

* After successful peripheral revascularisation and establishing haemostasis. † Xarelto 2.5 mg should be used with caution in ACS and CAD/PAD patients ≥75 years of age if co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine. The benefit-risk of the treatment should be individually assessed on a regular basis.1

BID, twice daily; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction; NNT, number needed to treat; OD, once daily; PAD, peripheral arterial disease; RRR, relative risk reduction

PP-XAR-ALL-2120-1

References

Bayer AG. Xarelto^® (rivaroxaban) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf. Bayer AG. Xarelto^® (rivaroxaban) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf. Return to content
Bonaca MP, et al. N Engl J Med 2020;382(21):1994–2004 Return to content
Aspirin Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4172/smpc. Aspirin Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4172/smpc. Return to content

RELATED PODCAST
CAD or symptomatic PAD discussion

RELATED VIDEOS
Coronary Artery Disease Causes and Consequences

DOSING GUIDE

PRACTICAL MANAGEMENT

PRESCRIBING INFORMATION

Prevention of Atherothrombotic Events in Peripheral Artery Disease